GORE INITIATES THE RELIEF CLINICAL STUDY EVALUATING PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF
CAUTION: Investigational device. Limited by United States law to investigational use.
Nov 1, 2022
Gore Completes First In-human Implants of the GORE® VIAFORT Vascular Stent
CAUTION: Investigational device. Limited by United States law to investigational use.W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior
Oct 28, 2022
GORE ACQUIRES INNAVASC MEDICAL, INC.
Acquisition of graft technology builds upon Gore’s dialysis access solutions
Aug 12, 2022
GORE RECEIVES FDA APPROVAL OF GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS FOR THE REPAIR OF LESIONS OF THE DESCENDING THORACIC AORTA
Approval brings first flexible, off-the-shelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment.
May 13, 2022
GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
CAUTION: Investigational device. Limited by United States law to investigational use.
Apr 12, 2022
GORE® CARDIOFORM SEPTAL OCCLUDER MARKS 10 YEARS OF IMPROVING LIVES
After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care.
Jan 19, 2022
Gore Receives FDA Approval for the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System
The innovative device and delivery system combine proven conformability with new levels of control.
Jan 6, 2021